Navigation Links
Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body
Date:4/30/2009

Latest radiosurgery solutions from Elekta discussed at the 2009 AANS Meeting

ATLANTA, April 30 /PRNewswire/ -- At the 2009 American Association of Neurological Surgeons (AANS) Annual Meeting, May 4-6 at the San Diego Convention Center, Elekta customers and personnel will discuss how Elekta's latest line of stereotactic treatment solutions is addressing some of the most challenging cases facing neurosurgeons and oncologists today.

Local Control of Brain Mets

Recent studies estimate that 25 percent of all cancer patients - particularly patients with melanoma, lung cancer, or advanced breast cancer - will develop brain metastases and require whole brain therapy. While whole brain radiotherapy is a treatment option, it also subjects healthy brain tissue to radiation dosages that may have negative side affects or limit the amount of therapeutic dose that can be applied in the event of a re-occurrence. In addition, whole brain radiation requires an interruption in the chemotherapy treatments that are so important to maintaining tumor control.

Dr. Christopher M. Duma, Neurological Surgeon at Hoag Memorial Hospital Presbyterian in Newport Beach, California will discuss the use of Leksell Gamma Knife(R) Perfexion(TM) to treat multiple brain metastases in a single session. Gamma Knife(R) surgery always has been especially good at treating very small targets with little or no damage to healthy tissue; but Perfexion is able to treat several targets faster and more efficiently making it a viable option of patients with brain metastases. The result is a fast and effective treatment for brain metastases that is easier on the patient, reduces the damage to healthy tissue that may limit future treatment options, and allows for concomitant chemotherapy for optimum primary tumor control.

Stereotactic Radiosurgery of the Spine

While Gamma Knife(R) surgery was initially invented to treat inoperable cancers and disorders in the brain, now the kind of stereotactic treatment precision established by Elekta can be applied to extra-cranial tumors. Today, the latest advancements in image guidance and dynamic arc delivery pioneered by Elekta combined with Leksell-quality fixation options support Stereotactic Radiosurgery (SRS) and Stereotactic Radiation Therapy (SRT) anywhere in the body to deliver optimal dose to the tumor, while protecting vital organs like the spinal cord.

Dr. Peter C. Gerszten, Associate Professor of Neurological Surgery and Radiation Oncology at the University of Pittsburgh Medical Center and co-editor of Spine Radiosurgery, will discuss the use of Elekta Axesse(TM) to perform stereotactic radiosurgery for spine and paraspinal lesions. According to Dr. Gerszten, "Axesse is fully optimized for SRS and SRT and therefore well suited for spine radiosurgery, providing patients a fast, safe, and effective treatment alternative or as an adjunct to open surgical intervention."

More than sixty years ago, Professor Lars Leksell developed a three-coordinate head frame and revolutionized the field of stereotaxy. Twenty years later he conceived of replacing the surgical precision of the neurosurgeon with precisely targeted radiation, and invented the field of stereotactic radiosurgery (SRS). Today, Leksell Gamma Knife(R) Perfexion(TM) is still the benchmark upon which all other SRS methods are measured; Perfexion equipped with Extend Program*(TM) is capable of treating cancers of the head and neck and lesions previously unsuitable for Gamma Knife surgery; And Elekta Axesse(TM) supports SRS and SRT anywhere in the body making it a versatile cross-over solution for neurosurgery and oncology.

According to President and CEO of Elekta North America, Joseph K. Jachinowski, "Since its very foundation, Elekta has sought to develop technology that allowed practitioners to achieve specific clinical objectives. Today Elekta Neuroscience is still developing technology to address the most challenging cases in neurosurgery and oncology, creating new treatment possibilities that are redefining what we call, human care."

*Extend requires 510(k) review and is not yet commercially available in the U.S.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages
2. Xoft Signs Sales Development Agreement With Elekta
3. Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement
4. Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer
5. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
6. CMS, Inc., an Elekta Company, Receives FDA 510(k) Clearance for Atlas-Based Autosegmentation Software
7. Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases
8. Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
10. Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness
11. Elekta Contract Provides MAGNET Cooperative Access to Leading Radiation Therapy Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
(Date:10/12/2017)... Texas (PRWEB) , ... October 12, 2017 , ... ... and biologics manufacturer, has expanded its executive staff with the addition of industry ... In this role, Slott will develop the national distribution and sales network, direct ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: